GT200600457A - Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 - Google Patents
Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2Info
- Publication number
- GT200600457A GT200600457A GT200600457A GT200600457A GT200600457A GT 200600457 A GT200600457 A GT 200600457A GT 200600457 A GT200600457 A GT 200600457A GT 200600457 A GT200600457 A GT 200600457A GT 200600457 A GT200600457 A GT 200600457A
- Authority
- GT
- Guatemala
- Prior art keywords
- inflatements
- cellular
- administration
- formula iii
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE AL ÁCIDO 2-(3-{6-[2-(2,4-DICLORO-FENIL)-ETILAMINO]-2-METOXI-PIRIMIDIN-4-IL]-FENIL)-2-METIL-PROPIONICO DEL ÁCIDO FOSFÓRICO DE FÓRMULA III, A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN UNA CANTIDAD FARMACÉUTICAMENTE EFECTIVA DEL COMPUESTO DE FÓRMULA III, Y A UN VEHÍCULO FARMACÉUTICAMENTE ACEPTABLE; Y UN MÉTODO DE TRATAR A UN PACIENTE QUE PADECE DE UN TRASTORNO MEDIADO POR PGD2 QUE INCLUYE, PERO NO SE LIMITA A, ENFERMEDAD ALÉRGICA (TAL COMO RINITIS ALÉRGICAS, CONJUNTIVITIS ALÉRGICA, DERMATITIS ATÓPICA, ASMA BRONQUIALY ALERGIA ALIMENTARIA), MASTOCITOSIS SISTÉMICA, TRASTORNOS ACOMPAÑADOS POR LA ACTIVACIÓN SISTÉMICA DE LOS MASTOCITOS, CHOQUE ANAFILÁCTICO, BRONCOCONSTRICCIÓN, BRONQUITIS, URTICARIA, ECZEMA, ENFERMEDADES ACOMPAÑADAS POR PICOR (TALES COMO DERMATITIS ATÓPICA Y URTICARIA), ENFERMEDADES (TALES COMO CATARATAS, DESPRENDIMIENTO DE RETINA, INFLAMACIÓN, INFECCIÓN Y TRASTORNOS DEL SUEÑO) QUE SE GENERAN DE FORMA SECUNDARIA COMO RESULTADO DE LA CONDUCTA ACOMPAÑADA POR PICOR (TAL COMO RASCARSE Y GOLPEARSE), INFLAMACIÓN, ENFERMEDADES PULMONARES OBSTRUCTIVAS CRÓNICAS, LESIÓN DE REPERFUSIÓN ISQUÉMICA, ACCIDENTE CEREBROVASCULAR, ARTRITIS REUMATOIDE CRÓNICA, PLEURESÍA, COLITIS ULCEROSA Y SIMILARES, ADMINISTRANDO A DICHO PACIENTE UNA CANTIDAD EFICAZ DEL COMPUESTO DE FÓRMULA III. T2006
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72629005P | 2005-10-13 | 2005-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200600457A true GT200600457A (es) | 2007-04-27 |
Family
ID=37963090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200600457A GT200600457A (es) | 2005-10-13 | 2006-10-11 | Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 |
Country Status (36)
Country | Link |
---|---|
US (1) | US7642249B2 (es) |
EP (1) | EP1948620B1 (es) |
JP (1) | JP2009511591A (es) |
KR (1) | KR101365480B1 (es) |
CN (1) | CN101287714B (es) |
AR (1) | AR058085A1 (es) |
AU (1) | AU2006304187B2 (es) |
BR (1) | BRPI0617311A2 (es) |
CA (1) | CA2625563C (es) |
CR (1) | CR9870A (es) |
DK (1) | DK1948620T3 (es) |
DO (2) | DOP2006000220A (es) |
EC (1) | ECSP088362A (es) |
ES (1) | ES2409833T3 (es) |
GT (1) | GT200600457A (es) |
HK (1) | HK1125133A1 (es) |
HN (1) | HN2008000603A (es) |
HR (1) | HRP20130341T1 (es) |
IL (1) | IL190673A (es) |
MA (1) | MA30005B1 (es) |
MY (1) | MY145648A (es) |
NI (1) | NI200800116A (es) |
NO (1) | NO20082072L (es) |
NZ (1) | NZ567433A (es) |
PE (1) | PE20070791A1 (es) |
PL (1) | PL1948620T3 (es) |
PT (1) | PT1948620E (es) |
RS (1) | RS52799B (es) |
RU (1) | RU2419614C2 (es) |
SI (1) | SI1948620T1 (es) |
TN (1) | TNSN08131A1 (es) |
TW (1) | TW200728288A (es) |
UA (1) | UA93062C2 (es) |
UY (1) | UY29862A1 (es) |
WO (1) | WO2007047378A2 (es) |
ZA (1) | ZA200802586B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
AR060403A1 (es) * | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
EA200802417A1 (ru) * | 2006-06-09 | 2009-06-30 | Икос Корпорейшн | Замещенные фенилуксусные кислоты как dp-2-антагонисты |
EP2170837B1 (en) * | 2007-06-29 | 2011-11-02 | Sanofi | Process for preparing 2-(3-{6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxypyrimidin-4-yl)-phenyl)-2-methylpropionic acid |
KR101235961B1 (ko) | 2008-02-01 | 2013-02-21 | 판미라 파마슈티칼스, 엘엘씨 | 프로스타글란딘 d2 수용체의 n,n-이치환 아미노알킬비페닐 길항제 |
JP2011513242A (ja) | 2008-02-25 | 2011-04-28 | アミラ ファーマシューティカルズ,インク. | プロスタグランジンd2受容体アンタゴニスト |
GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
US20100112606A1 (en) * | 2008-10-17 | 2010-05-06 | Michael Armstrong | Measurement and analysis of leukotrienes |
AR074776A1 (es) * | 2008-12-18 | 2011-02-09 | Sanofi Aventis | Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente |
CN102596199A (zh) | 2009-07-31 | 2012-07-18 | 潘米拉制药公司 | Dp2受体拮抗剂的眼用医药组合物 |
KR20120047273A (ko) | 2009-08-05 | 2012-05-11 | 판미라 파마슈티칼스, 엘엘씨 | Dp2 길항제 및 이의 용도 |
EP2590640A1 (en) | 2010-07-08 | 2013-05-15 | Ramot at Tel-Aviv University Ltd | Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions |
EP2621276B1 (en) * | 2010-09-30 | 2017-12-27 | Merck Sharp & Dohme Corp. | 2-alkoxy pyrimidine pde10 inhibitors |
WO2014066568A1 (en) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
CN113773257A (zh) | 2015-06-04 | 2021-12-10 | 奥瑞基尼探索技术有限公司 | 用作cdk抑制剂的经过取代的杂环衍生物 |
CA3075688A1 (en) | 2017-09-13 | 2019-03-21 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1474147B1 (en) * | 2001-12-07 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Pyrimidine-based compounds useful as gsk-3 inhibitors |
JP2009513521A (ja) * | 2003-07-09 | 2009-04-02 | エフ.ホフマン−ラ ロシュ アーゲー | プロスタグランジンi2アンタゴニストとしてのチオフェニルアミノイミダゾリン類 |
HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
-
2006
- 2006-10-11 GT GT200600457A patent/GT200600457A/es unknown
- 2006-10-12 PT PT68258367T patent/PT1948620E/pt unknown
- 2006-10-12 AU AU2006304187A patent/AU2006304187B2/en not_active Ceased
- 2006-10-12 JP JP2008535672A patent/JP2009511591A/ja not_active Abandoned
- 2006-10-12 UA UAA200806196A patent/UA93062C2/ru unknown
- 2006-10-12 MY MYPI20081085A patent/MY145648A/en unknown
- 2006-10-12 NZ NZ567433A patent/NZ567433A/en not_active IP Right Cessation
- 2006-10-12 CN CN2006800378860A patent/CN101287714B/zh not_active Expired - Fee Related
- 2006-10-12 KR KR1020087008805A patent/KR101365480B1/ko not_active IP Right Cessation
- 2006-10-12 SI SI200631572T patent/SI1948620T1/sl unknown
- 2006-10-12 RU RU2008118491/04A patent/RU2419614C2/ru not_active IP Right Cessation
- 2006-10-12 BR BRPI0617311-0A patent/BRPI0617311A2/pt not_active IP Right Cessation
- 2006-10-12 ES ES06825836T patent/ES2409833T3/es active Active
- 2006-10-12 EP EP06825836A patent/EP1948620B1/en active Active
- 2006-10-12 WO PCT/US2006/039901 patent/WO2007047378A2/en active Application Filing
- 2006-10-12 DK DK06825836.7T patent/DK1948620T3/da active
- 2006-10-12 CA CA2625563A patent/CA2625563C/en not_active Expired - Fee Related
- 2006-10-12 RS RS20130225A patent/RS52799B/en unknown
- 2006-10-12 PL PL06825836T patent/PL1948620T3/pl unknown
- 2006-10-12 AR ARP060104475A patent/AR058085A1/es not_active Application Discontinuation
- 2006-10-12 PE PE2006001242A patent/PE20070791A1/es not_active Application Discontinuation
- 2006-10-13 TW TW095137635A patent/TW200728288A/zh unknown
- 2006-10-13 UY UY29862A patent/UY29862A1/es unknown
- 2006-10-13 DO DO2006000220A patent/DOP2006000220A/es unknown
- 2006-10-13 DO DO2006P000223A patent/DOP2006000223A/es unknown
-
2008
- 2008-03-19 TN TNP2008000131A patent/TNSN08131A1/en unknown
- 2008-03-20 ZA ZA200802586A patent/ZA200802586B/xx unknown
- 2008-04-07 IL IL190673A patent/IL190673A/en not_active IP Right Cessation
- 2008-04-07 CR CR9870A patent/CR9870A/es not_active Application Discontinuation
- 2008-04-10 EC EC2008008362A patent/ECSP088362A/es unknown
- 2008-04-11 US US12/101,282 patent/US7642249B2/en not_active Expired - Fee Related
- 2008-04-11 NI NI200800116A patent/NI200800116A/es unknown
- 2008-04-11 HN HN2008000603A patent/HN2008000603A/es unknown
- 2008-05-02 MA MA30890A patent/MA30005B1/fr unknown
- 2008-05-02 NO NO20082072A patent/NO20082072L/no not_active Application Discontinuation
-
2009
- 2009-04-14 HK HK09103427.8A patent/HK1125133A1/xx not_active IP Right Cessation
-
2013
- 2013-04-17 HR HRP20130341TT patent/HRP20130341T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200600457A (es) | Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 | |
CR9003A (es) | 2,6 sustituido-4-monosustituido amino-pirimidinas como antagonistas del repector de prostaglandina d2 | |
DOP2006000016A (es) | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. | |
ECSP088813A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 | |
NO20083567L (no) | Hydantoinderivater for behandling av inflammatoriske forstyrrelser | |
EA201270561A1 (ru) | Антагонисты рецептора cgrp | |
TNSN08515A1 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
CY1118021T1 (el) | Παραγωγο αζολιου | |
WO2009126530A3 (en) | Piperidine derivatives as cgrp receptor antagonists | |
WO2011089396A3 (en) | Pyruvamide compounds as inhibitors of dust mite group 1 peptidase allergen | |
SV2008002868A (es) | Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2 | |
WO2012029032A3 (en) | Heterocyclic compounds as dgat1 inhibitors | |
UA95303C2 (en) | 2-phenyl-indoles as prostaglandin d2 receptor antagonists | |
CY1114902T1 (el) | Ανταγωνιστες cgrp υποδοχεα | |
CY1113582T1 (el) | 2,6-υποκατεστημενες-4-μονοϋποκατεστημενες amino-πυριμιδινες ως ανταγωνιστες υποδοχεων d2 των προσταγλανδινων |